Gastroesophageal Reflux Disease
'Relief Starts with Awareness' campaign aims to shed light on GERD symptoms, treatments
To honor GERD Awareness Week on Nov. 24 to 30, the International Foundation for Gastrointestinal Disorders launched a campaign theme, “Relief Starts with Awareness,” to boost understanding of symptoms and treatments for the disease.
COPD plus GERD reduces mortality, ventilation odds in hospitalized patients
BOSTON — The odds for mortality, ventilation and septic shock among adults hospitalized with COPD went down if they also had GERD, according to data presented at the CHEST Annual Meeting.
FDA expands Voquezna approval for heartburn relief in non-erosive GERD
The FDA has expanded approval for Phathom Pharmaceuticals’ Voquezna tablets 10 mg to alleviate heartburn related in non-erosive gastroesophageal reflux disease, according to a company press release.
Multiple comorbidities, triggers associated with chronic cough
WASHINGTON — Asthma was the most common comorbidity associated with chronic cough in the findings of a poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
On-demand vonoprazan may replace daily therapy for nonerosive reflux disease
Researchers reported that on-demand vonoprazan may be a “reasonable alternative” to daily therapy for heartburn, after demonstrating complete and sustained relief of more heartburn episodes than placebo.
Mepolizumab improves outcomes in patients with asthma, related comorbidities
Outcomes improved for patients with severe asthma who took mepolizumab regardless of their other comorbidities, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.
Voquezna back on track with FDA approval for erosive esophagitis, heartburn relief
The FDA has approved Phathom Pharmaceuticals’ Voquezna tablets 10 mg and 20 mg to treat erosive esophagitis, or erosive gastroesophageal reflux disease, and alleviate heartburn associated with the disease, noted a company release.
FDA approves reformulated Voquezna Triple, Dual Pak for H. pylori infection
The FDA has approved the prior approval supplement for Phathom Pharmaceutical’s reformulated vonoprazan tablets for its Voquezna Triple Pak and Voquezna Dual Pak to treat adults with Helicobacter pylori infection, according to a company release.
World Trade Center firefighters using inhaled medication, steroids at risk for GERD
HONOLULU — Use of short-acting beta agonists and steroids each raised the likelihood for gastroesophageal reflux disease among firefighters exposed to 9/11 particulate matter, according to a presentation at the CHEST Annual Meeting.
Consistent CPAP use lowers odds for gastroesophageal reflux, wheeze, cough
The likelihood for nocturnal gastroesophageal reflux, wheeze and cough declined with use of positive airway pressure for 2 years in patients with obstructive sleep apnea, according to results published in ERJ Open Research.